Role of pamidronate disodium in the treatment of metastatic bone disease.

摘要: Aims and background Bone metastases are a common feature of advanced neoplastic disease considered to be among the most frequent causes pain complications in oncologic patients. The main objective treatment such patients is control their symptoms improve quality life. Pamidronate disodium second-generation bisphosphonate capable inhibiting bone resorption (particularly osteoclast activity) without affecting remineralization. After brief introduction concerning pathophysiology pain, we herein present data on clinical pharmacology toxicity bisphosphonates general, pamidronate particular. We conclude by reviewing literature use phase II III trials involving with metastatic disease. Methods paper based review articles published between 1984 1997 selected from Cancerline Medline databases. Results In studies (breast cancer multiple myeloma particular), proved efficacious reducing incidence skeletal complications, decreasing excretion metabolic markers improving Intravenous infusions 60-90 mg over period 2 hr every 3-4 weeks did not cause any significant toxic effects was easily managed. Conclusions that symptomatic can an important therapeutic option association systemic treatments, radiotherapy normal supportive care, especially breast myeloma. Further randomized necessary confirm positive preliminary results other neoplasms, analyze cost/benefit ratio treatment, verify possibility that, addition being used for palliative purposes, may also prevent or delay appearance metastases.